Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. (Q52894311)

9 May 2018

title

Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. (English)

1 reference

9 May 2018

author name string

Ralf Wassmuth

1

1 reference

9 May 2018

Hassan Abdel-Aty

2

1 reference

9 May 2018

Steffen Bohl

3

1 reference

9 May 2018

Jeanette Schulz-Menger

4

1 reference

9 May 2018

language of work or name

English

0 references

publication date

29 March 2011

1 reference

9 May 2018

published in

European Radiology

1 reference

9 May 2018

volume

21

1 reference

9 May 2018

page(s)

1643-1650

1 reference

9 May 2018

issue

8

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s00330-011-2109-3

exact match

0 references

cites work

Diagnosis and management of the cardiac amyloidoses

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Evaluation and management of the cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Risk stratification in cardiac amyloidosis: novel approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

How we perform delayed enhancement imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Myocardial late enhancement in contrast-enhanced cardiac MRI: distinction between infarction scar and non-infarction-related disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Non-ischemic causes of delayed myocardial hyperenhancement on MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Cardiovascular magnetic resonance in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

MRI assessment of cardiac amyloidosis: experience of six cases with review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Normalized Left Ventricular Systolic and Diastolic Function by Steady State Free Precession Cardiovascular Magnetic Resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Focal amyloidosis of the head and neck: evaluation with CT and MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Pleural effusions in systemic amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

MR findings in cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Amyloidosis of the heart and respiratory system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00330-011-2109-3

Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy

21 January 2018

1 reference

12 December 2020

Differentiation of cardiac amyloidosis and hypertrophic cardiomyopathy. A comparison of familial amyloidosis with polyneuropathy and hypertrophic cardiomyopathy by electrocardiography and echocardiography

1 reference

12 December 2020

Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy

1 reference

12 December 2020

Atrial dimensions in health and left ventricular disease using cardiovascular magnetic resonance

1 reference

12 December 2020

Cardiac amyloidosis: typical imaging findings and diffuse myocardial damage demonstrated by delayed contrast-enhanced MRI

1 reference

12 December 2020

Value of cardiovascular magnetic resonance for determining cardiac involvement in systemic amyloidosis

1 reference

12 December 2020

Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis

1 reference

12 December 2020

Noninvasive diagnosis of biopsy-proven cardiac amyloidosis

1 reference

12 December 2020

Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis

1 reference

12 December 2020

Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy

1 reference

12 December 2020

Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients

1 reference

12 December 2020

Delayed hyper-enhancement magnetic resonance imaging provides incremental diagnostic and prognostic utility in suspected cardiac amyloidosis

1 reference

12 December 2020

CT and MR imaging of localized amyloidosis

1 reference

12 December 2020

Atrial enhancement by cardiovascular magnetic resonance in cardiac amyloidosis

1 reference

12 December 2020

Cardiac amyloidosis: MR imaging findings and T1 quantification, comparison with control subjects

1 reference

12 December 2020

Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease

1 reference

12 December 2020

Assessment of restrictive cardiomyopathy of amyloid or idiopathic etiology by magnetic resonance imaging.

1 reference

12 December 2020

Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation

1 reference

12 December 2020

Atrial pathology in cardiac amyloidosis: evidence from ECG and cardiovascular magnetic resonance

1 reference

12 December 2020

10.1007/S00330-011-2109-3

Identifiers

DOI

1 reference

9 May 2018

PubMed ID

21720941

1 reference

9 May 2018